ClinicalTrials.gg
CompletedNCT03006705Updated May 3, 2024

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

A Phase 3 interventional study of Nivolumab and Tegafur-gimeracil-oteracil potassium in Gastric Cancer, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 108 sites in 4 countries. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-03.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies testing nivolumab in Stomach Neoplasms — 6 open to participants now, 13 under way, 2 of them phase 3. Nivolumab · Stomach Neoplasms.

Enrollment
3rd of 30
800 · median 49
Started
2017
with 3 others
Phase 3
6 of 30
1 open now
Registered
7th of 30
by date
Lead sponsor
3 of 30
Ono Pharmaceutical Co. Ltd

Among the 30 studies testing nivolumab in Stomach Neoplasms, this one is the 3rd largest by enrollment, is one of 4 that started in 2017, is one of 6 in phase 3, and was the 7th registered.

Stomach Neoplasms

3,406 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

6 of the 30 studies testing nivolumab in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing nivolumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.

03

Conditions studied

  • Gastric Cancer

Browse trials for

Keywords

  • ONO-4538,BMS-936558,Nivolumab,gastric,adjuvant,S-1,CapeOX
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with confirmed adenocarcinoma of the stomach
  • Patients without a remnant cancer (R0) who have undergone gastrectomy
  • Gastric carcinoma according to the stage classification of AJCC/UICC TNM Classification, 7th Edition on the basis of overall postoperative findings
  • (ECOG) Performance Status (PS) score of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Patients who have received non-surgical treatment (e.g., radiotherapy, chemotherapy, hormone therapy) for gastric cancer
  • Multiple primary cancers
  • A current or past history of severe to any other antibody products
  • Any concurrent disease or past history of chronic or recurrent autoimmune disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
800 participants (actual)

Study arms

  • Experimental
    Nivolumab group

    Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year). Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator. S-1 therapy(maximum 1 year): Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off CapeOX Therapy(maximum 6 months): Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off. Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.

    Drug: Nivolumab · Drug: Tegafur-gimeracil-oteracil potassium · Drug: Oxaliplatin · Drug: Capecitabine

  • Placebo comparator
    Placebo group

    Placebo: Placebo solution intravenously for 30 min in every 3 weeks (maximum 1 year). Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator. S-1 therapy(maximum 1 year): Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off CapeOX Therapy(maximum 6 months): Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off. Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.

    Drug: Tegafur-gimeracil-oteracil potassium · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Placebo

Interventions

  • Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).

    Also known as: BMS-936558, ONO-4538, MDX-1106

  • Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off

  • Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.

  • Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.

  • DrugPlacebo

    Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).

06

What researchers measure

Primary outcomes

  1. Relapse-free survival (RFS)

    Time frame: 5 years

Secondary outcomes

  1. Overall survival (OS)

    Time frame: 5 years

  2. 3-year OS rate

    Time frame: 3 years

  3. 5-year OS rate

    Time frame: 5 years

  4. 3-year RFS rate

    Time frame: 3 years

  5. 5-year RFS rate

    Time frame: 5 years

  6. Safety will be analyzed through the incidence of adverse events, serious adverse events

    Time frame: Up to 28 days from last dose

  7. Safety will be analyzed through the incidence of laboratory abnormalities

    Time frame: Up to 28 days from last dose

07

Study locations

108 sites
  • Anhui Province Clinical Site
    Anhui Province, China
  • Beijing Clinical Site1
    Beijing, China
  • Beijing Clinical Site2
    Beijing, China
  • Cuangdong Province Clinical Site
    Cuangdong Province, China
  • Guangdong Province Clinical Site1
    Guangdong Province, China
  • Guangdong Province Clinical Site2
    Guangdong Province, China
  • Henan Province Clinical Site1
    Henan Province, China
  • Henan Province Clinical Site2
    Henan Province, China
  • Jiangsu Province Clinical Site1
    Jiangsu Province, China
  • Jiangsu Province Clinical Site3
    Jiangsu Province, China
  • Jiangsu Province Clinical Site4
    Jiangsu Province, China
  • Jiangsu Province Clinical Site5
    Jiangsu Province, China
  • Jiangsu Province Clinical Site6
    Jiangsu Province, China
  • Jiangxi Province Clinical Site2
    Jiangxi Province, China
  • Jilin Province Clinical Site
    Jilin Province, China
  • Liaoning Province Clinical Site
    Liaoning Province, China
  • Shanxi Province Clinical Site
    Shanxi Province, China
  • Tianjin Clinical Site1
    Tianjin, China
  • Tianjin Clinical Site2
    Tianjin, China
  • Zhejiang Province Clinical Site
    Zhejiang Province, China
  • Zhengjiang Province Clinical Site
    Zhengjiang Province, China
  • Aichi Clinical Site1
    Nagoya, Aichi, Japan
  • Aichi Clinical Site2
    Nagoya, Aichi, Japan
  • Chiba Clinical Site
    Kamogawa, Chiba, Japan
  • Ehime Clinical Site
    Matsuyama, Ehime, Japan
  • Ehime Clinicla Site
    Matsuyama, Ehime, Japan
  • Gifu Clinical Site
    Ōgaki, Gifu, Japan
  • Gunma Clinical Site
    Ota, Gunma, Japan
  • Gunma Clinical Site
    Takasaki, Gunma, Japan
  • Hiroshima Clinical Site
    Fukuyama, Hiroshima, Japan
  • Hokkaido Clinical Site 3
    Hakodate, Hokkaido, Japan
  • Hokkaido Clinical Site 1
    Sapporo, Hokkaido, Japan
  • Hokkaido Clinical Site2
    Sapporo, Hokkaido, Japan
  • Hyogo Clinical Site
    Akashi, Hyogo, Japan
  • Hyogo Clinical Site
    Amagasaki, Hyogo, Japan
  • Hyogo Clinical Site
    Nishinomiya, Hyogo, Japan
  • Ishikawa Clinical Site
    Kanazawa, Ishikawa, Japan
  • Iwate Clinical Site
    Morioka, Iwate, Japan
  • Kanagawa Clinical Site
    Sagamihara, Kanagawa, Japan
  • Kanagawa Clinical Site
    Yokohama, Kanagawa, Japan
  • Miyagi Clinical Site
    Osaki, Miyagi, Japan
  • Nagano Clinical Site
    Saku, Nagano, Japan
  • Okayama Clinical Site
    Kurashiki, Okayama, Japan
  • Osaka Clinical Site
    Hirakata, Osaka, Japan
  • Osaka Clinical Site
    Sakai, Osaka, Japan
  • Osaka Clinical Site
    Suita, Osaka, Japan
  • Osaka Clinical Site
    Takatsuki, Osaka, Japan
  • Osaka Clinical Site
    Toyonaka, Osaka, Japan
  • Osaka Clinical Site
    Ōsaka-sayama, Osaka, Japan
  • Saitama Clinical Site
    Hidaka, Saitama, Japan
  • Saitama Clinical Site
    Kitaadachi-gun, Saitama, Japan
  • Shizuoka Clinical Site
    Sunto-gun, Shizuoka, Japan
  • Tochigi Clinical Site
    Shimotsuke, Tochigi, Japan
  • Tokyo Clinical Site
    Bunkyo-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Chuo-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Koto-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Shinjuku-ku, Tokyo, Japan
  • Chiba Clinical Site
    Chiba, Japan
  • Fukuoka Clinical Site 1
    Fukuoka, Japan
  • Fukuoka Clinical Site 2
    Fukuoka, Japan
  • Gifu Clinical Site
    Gifu, Japan
  • Hiroshima Clinical Site1
    Hiroshima, Japan
  • Hiroshima Clinical Site2
    Hiroshima, Japan
  • Hiroshima Clinical Site3
    Hiroshima, Japan
  • Kochi Clinical Site
    Kochi, Japan
  • Kumamoto Clinical Site
    Kumamoto, Japan
  • Kyoto Clinical Site
    Kyoto, Japan
  • Niigata Clinical Site
    Niigata, Japan
  • Osaka Clinical Site1
    Osaka, Japan
  • Osaka Clinical Site2
    Osaka, Japan
  • Osaka Clinical Site3
    Osaka, Japan
  • Osaka Clinical Site4
    Osaka, Japan
  • Shizuoka Clinical Site
    Shizuoka, Japan
  • Toyama Clinical Site
    Toyama, Japan
  • Wakayama Clinical Site
    Wakayama, Japan
  • Yamagata Clinical Site
    Yamagata, Japan
  • Busan Clinical Site1
    Busan, Korea, Republic of
  • Busan Clinical Site2
    Busan, Korea, Republic of
  • Busan Clinical Site3
    Busan, Korea, Republic of
  • Daegu Clinical Site1
    Daegu, Korea, Republic of
  • Daegu Clinical Site2
    Daegu, Korea, Republic of
  • Daegu Clinical Site3
    Daegu, Korea, Republic of
  • Daejeon Clinical Site 1
    Daejeon, Korea, Republic of
  • Daejeon Clinical Site 2
    Daejeon, Korea, Republic of
  • Gwangju Clinical Site
    Gwangju, Korea, Republic of
  • Gyeonggi-do Clinical Site1
    Gyeonggi-do, Korea, Republic of
  • Gyeonggi-do Clinical Site2
    Gyeonggi-do, Korea, Republic of
  • Gyeonggi-do Clinical Site3
    Gyeonggi-do, Korea, Republic of
  • Gyeonggi-do Clinical Site4
    Gyeonggi-do, Korea, Republic of
  • Gyeonggi-do Clinical Site5
    Gyeonggi-do, Korea, Republic of
  • Jeollabuk-do Clinical Site
    Jeollabuk-do, Korea, Republic of
  • Seoul Clinical Site 8
    Seoul, Korea, Republic of
  • Seoul Clinical Site 9
    Seoul, Korea, Republic of
  • Seoul Clinical Site1
    Seoul, Korea, Republic of
  • Seoul Clinical Site2
    Seoul, Korea, Republic of
  • Seoul Clinical Site3
    Seoul, Korea, Republic of
  • Seoul Clinical Site4
    Seoul, Korea, Republic of
  • Seoul Clinical Site5
    Seoul, Korea, Republic of
  • Seoul Clinical Site6
    Seoul, Korea, Republic of
  • Seoul Clinical Site7
    Seoul, Korea, Republic of

Showing the first 100 of 108 sites across 4 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Chang X, Ge X, Zhang Y, Xue X. The current management and biomarkers of immunotherapy in advanced gastric cancer. Medicine (Baltimore). 2022 May 27;101(21):e29304. doi: 10.1097/MD.0000000000029304. PubMed 35623069 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Aug 2022, 66 months.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 66 months is above that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2016
First posted
Dec 30, 2016
StartActual
Jan 31, 2017
Primary completionActual
Aug 17, 2022
CompletionActual
Mar 31, 2023
Last update
May 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03006705
Responsible party
Sponsor
First posted
Dec 30, 2016
Start date
Jan 31, 2017
Primary completion
Aug 17, 2022
Completion
Mar 31, 2023
Last update
May 3, 2024

Study contacts

Project Leader
study director · Ono Pharmaceutical Co. Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion